Literature DB >> 12607581

Palliative and postoperative radiotherapy in biliary tract cancer.

O Kenneth Macdonald1, Christopher H Crane.   

Abstract

Local failure is the primary limitation for cure in patients with BTC. whether or not they have been resected. The use of radiotherapy with or without chemotherapy in the postoperative setting is controversial, but some studies have reported improvement in 5-year survival. In patients with unresectable BTC, EBRT offers effective palliation of symptomatic disease and has resulted in improved median and long-term survival in a small number of patients in most studies. Novel approaches, including neoadjuvant chemoradiotherapy combined with OLT, and escalated conformal irradiation, seem to be promising and warrant further investigation.

Entities:  

Mesh:

Year:  2002        PMID: 12607581     DOI: 10.1016/s1055-3207(02)00038-8

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  13 in total

1.  Operative considerations in resection of hilar cholangiocarcinoma.

Authors:  Alexander A Parikh; Eddie K Abdalla; Jean-Nicolas Vauthey
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

2.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers.

Authors:  Al B Benson; Thomas A Abrams; Edgar Ben-Josef; P Mark Bloomston; Jean F Botha; Bryan M Clary; Anne Covey; Steven A Curley; Michael I D'Angelica; Rene Davila; William D Ensminger; John F Gibbs; Daniel Laheru; Mokenge P Malafa; Jorge Marrero; Steven G Meranze; Sean J Mulvihill; James O Park; James A Posey; Jasgit Sachdev; Riad Salem; Elin R Sigurdson; Constantinos Sofocleous; Jean-Nicolas Vauthey; Alan P Venook; Laura Williams Goff; Yun Yen; Andrew X Zhu
Journal:  J Natl Compr Canc Netw       Date:  2009-04       Impact factor: 11.908

3.  Intrahepatic cholangiocarcinoma: expert consensus statement.

Authors:  Sharon M Weber; Dario Ribero; Eileen M O'Reilly; Norihiro Kokudo; Masaru Miyazaki; Timothy M Pawlik
Journal:  HPB (Oxford)       Date:  2015-08       Impact factor: 3.647

4.  Impact of adjuvant chemoradiation on survival in patients with resectable cholangiocarcinoma.

Authors:  Laura L Dover; Robert A Oster; Andrew M McDonald; Derek A DuBay; Thomas N Wang; Rojymon Jacob
Journal:  HPB (Oxford)       Date:  2016-08-16       Impact factor: 3.647

5.  Strategies for resection using portal vein embolization: hepatocellular carcinoma and hilar cholangiocarcinoma.

Authors:  Daniel A Anaya; Dan G Blazer; Eddie K Abdalla
Journal:  Semin Intervent Radiol       Date:  2008-06       Impact factor: 1.513

6.  Patterns of Failure and the Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation.

Authors:  Edward Christopher Dee; Morgan E Freret; Nora Horick; Ann C Raldow; Lipika Goyal; Andrew X Zhu; Aparna R Parikh; David P Ryan; Jeffrey W Clark; Jill N Allen; Cristina R Ferrone; Carlos Fernandez-Del Castillo; Kenneth K Tanabe; Lorraine C Drapek; Theodore S Hong; Motaz Qadan; Jennifer Y Wo
Journal:  Ann Surg Oncol       Date:  2020-08-01       Impact factor: 5.344

7.  Chemotherapy for cholangiocarcinoma: An update.

Authors:  Natalia Ramírez-Merino; Santiago Ponce Aix; Hernán Cortés-Funes
Journal:  World J Gastrointest Oncol       Date:  2013-07-15

8.  Chemoradiotherapy versus chemotherapy alone for unresected intrahepatic cholangiocarcinoma: practice patterns and outcomes from the national cancer data base.

Authors:  Vivek Verma; Adams Kusi Appiah; Tim Lautenschlaeger; Sebastian Adeberg; Charles B Simone; Chi Lin
Journal:  J Gastrointest Oncol       Date:  2018-06

9.  Two cases of humoral hypercalcemia of malignancy in metastatic cholangiocarcinoma.

Authors:  Seungtaek Lim; Jungwoo Han; Kyeong Hye Park; Won Jai Jung; Yong Kang Lee; Ara Choi; Young Jae Kim; Jong-Chan Lee; Hye Jin Choi
Journal:  Cancer Res Treat       Date:  2013-06-30       Impact factor: 4.679

10.  Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials.

Authors:  Ishwaria M Subbiah; Vivek Subbiah; Apostolia M Tsimberidou; Aung Naing; Ahmed O Kaseb; Milind Javle; Siqing Fu; David S Hong; Sarina Piha-Paul; Jennifer J Wheler; Kenneth R Hess; Filip Janku; Gerald S Falchook; Robert A Wolff; Razelle Kurzrock
Journal:  Oncotarget       Date:  2013-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.